Business Context and Reporting Period
This Form 8-K is filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp as indicated in metadata) for the reporting period ending April 30, 2019. The filing addresses a corporate governance event involving the death of a director and the subsequent impact on the company's compliance with NASDAQ listing rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Director Departure: On April 5, 2019, Marc W. Robbins, one of the company's three independent directors, passed away.
- Listing Non-Compliance: On April 26, 2019, the company received notice from NASDAQ indicating non-compliance with Listing Rule 5605 regarding the requirement for a majority of independent directors on the board and audit committee.
Outlook, Risks, and Management Commentary
CEO Robert A. Berman issued a press release expressing condolences and noting the irony that Mr. Robbins died from chronic venous insufficiency, the disease the company's VenoValve product aims to treat. The company has initiated a search for a replacement independent director. The company has until the earlier of its next annual shareholders' meeting or April 7, 2020, to demonstrate compliance with NASDAQ independence requirements.
Investor Verification Checklist
- Verify the current composition of the Board of Directors to confirm the number of independent directors.
- Monitor the timeline for appointing a new independent director to ensure compliance with the April 7, 2020 deadline.
- Review the attached press release (Exhibit 99.1) for additional details on the company's strategic direction following the director's passing.